Biolinerx Stock Today
| BLRX Stock | USD 0.62 0.02 3.13% |
Performance0 of 100
| Odds Of DistressOver 83
|
BioLineRx is trading at 0.62 as of the 22nd of May 2024; that is -3.13% down since the beginning of the trading day. The stock's open price was 0.64. BioLineRx has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for BioLineRx are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of June 2022 and ending today, the 22nd of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of July 2011 | Category Healthcare | Classification Health Care |
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modiin, Israel. Biolinerx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 79.94 M outstanding shares of which 410.59 K shares are currently shorted by private and institutional investors with about 1.21 trading days to cover. More on BioLineRx
Moving together with BioLineRx Stock
| 0.78 | DRMA | Dermata Therapeutics | PairCorr |
| 0.73 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
| 0.71 | BMY | Bristol Myers Squibb | PairCorr |
| 0.87 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against BioLineRx Stock
| 0.83 | SNDL | SNDL Inc | PairCorr |
| 0.55 | MRK | Merck Company Earnings Call This Week | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
BioLineRx Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BioLineRx's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BioLineRx or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Vice President-Development | Ella Sorani | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering BioLineRx report their recommendations after researching BioLineRx's financial statements, talking to executives and customers, or listening in on BioLineRx's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering BioLineRx. The BioLineRx consensus assessment is calculated by taking the average forecast from all of the analysts covering BioLineRx. | |||||
BioLineRx's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to BioLineRx's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioLineRx's financial leverage. It provides some insight into what part of BioLineRx's total assets is financed by creditors.
| |||||
BioLineRx (BLRX) is traded on NASDAQ Exchange in USA. It is located in Modi?in Technology Park, Hevel Modi'in, Israel, 7177871 and employs 79 people. BioLineRx is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 51.39 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioLineRx's market, we take the total number of its shares issued and multiply it by BioLineRx's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BioLineRx conducts business under Biotechnology sector and is part of Health Care industry. The entity has 79.94 M outstanding shares of which 410.59 K shares are currently shorted by private and institutional investors with about 1.21 trading days to cover.
BioLineRx currently holds about 43.15 M in cash with (22.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check BioLineRx Probability Of Bankruptcy
Ownership AllocationBioLineRx retains a total of 79.94 Million outstanding shares. BioLineRx shows 8.54 percent of its outstanding shares held by insiders and 1.7 percent owned by other corporate entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check BioLineRx Ownership Details
BioLineRx Stock Institutional Holders
Institutional Holdings refers to the ownership stake in BioLineRx that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BioLineRx's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioLineRx's value.| Instituion | Recorded On | Shares | |
| Jpmorgan Chase & Co | 2023-12-31 | 23 K | |
| National Asset Management Inc | 2023-12-31 | 19.3 K | |
| Rhumbline Advisers | 2023-12-31 | 18.8 K | |
| Northrock Partners Llc | 2023-12-31 | 17.1 K | |
| Cutter & Co Brokerage, Inc. | 2024-03-31 | 16.7 K | |
| Allen, Mooney & Barnes Investment Advisors, Llc | 2023-12-31 | 15 K | |
| Creative Planning Inc | 2023-12-31 | 14.6 K | |
| Advisor Group Holdings, Inc. | 2023-12-31 | 14.3 K | |
| Cetera Investment Advisers | 2023-12-31 | 10.9 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 238.3 K | |
| Values First Advisors Inc | 2024-03-31 | 203.6 K |
BioLineRx Historical Income Statement
BioLineRx Income Statement is one of the three primary financial statements used for reporting BioLineRx's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of BioLineRx revenue and expense. BioLineRx Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, BioLineRx's Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 17.5 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.1 M in 2024. View More FundamentalsBioLineRx Stock Against Markets
Picking the right benchmark for BioLineRx stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in BioLineRx stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for BioLineRx is critical whether you are bullish or bearish towards BioLineRx at a given time. Please also check how BioLineRx's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in BioLineRx without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated |
| All Next | Launch Module |
BioLineRx Corporate Management
Elected by the shareholders, the BioLineRx's board of directors comprises two types of representatives: BioLineRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLineRx. The board's role is to monitor BioLineRx's management team and ensure that shareholders' interests are well served. BioLineRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLineRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA | Chief Officer | Profile | |
| Raziel Fried | Treasurer Director | Profile | |
| Adam Esq | General Compliance | Profile | |
| Jael MSc | QA RA | Profile | |
| CPA MBA | Chief Officer | Profile |
How to buy BioLineRx Stock?
Before investing in BioLineRx, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in BioLineRx. To buy BioLineRx stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of BioLineRx. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase BioLineRx stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located BioLineRx stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased BioLineRx stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as BioLineRx, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.
Already Invested in BioLineRx?
The danger of trading BioLineRx is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of BioLineRx is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than BioLineRx. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile BioLineRx is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether BioLineRx offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioLineRx's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biolinerx Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biolinerx Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for BioLineRx Stock analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is BioLineRx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioLineRx. If investors know BioLineRx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioLineRx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.075 | Return On Assets (0.38) | Return On Equity (1.89) |
The market value of BioLineRx is measured differently than its book value, which is the value of BioLineRx that is recorded on the company's balance sheet. Investors also form their own opinion of BioLineRx's value that differs from its market value or its book value, called intrinsic value, which is BioLineRx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioLineRx's market value can be influenced by many factors that don't directly affect BioLineRx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioLineRx's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioLineRx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioLineRx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.